Logo image of NUVA

NUVASIVE INC (NUVA) Stock Fundamental Analysis

NASDAQ:NUVA - Nasdaq - US6707041058 - Common Stock - Currency: USD

39.75  -0.91 (-2.24%)

After market: 39.88 +0.13 (+0.33%)

Fundamental Rating

4

NUVA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. While NUVA is still in line with the averages on profitability rating, there are concerns on its financial health. NUVA has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

NUVA had positive earnings in the past year.
NUVA had a positive operating cash flow in the past year.
In multiple years NUVA reported negative net income over the last 5 years.
Each year in the past 5 years NUVA had a positive operating cash flow.
NUVA Yearly Net Income VS EBIT VS OCF VS FCFNUVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M 200M

1.2 Ratios

NUVA's Return On Assets of 1.36% is fine compared to the rest of the industry. NUVA outperforms 75.38% of its industry peers.
NUVA has a Return On Equity of 3.19%. This is in the better half of the industry: NUVA outperforms 76.38% of its industry peers.
NUVA has a Return On Invested Capital of 3.43%. This is in the better half of the industry: NUVA outperforms 76.38% of its industry peers.
NUVA had an Average Return On Invested Capital over the past 3 years of 2.87%. This is significantly below the industry average of 7.89%.
The 3 year average ROIC (2.87%) for NUVA is below the current ROIC(3.43%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.36%
ROE 3.19%
ROIC 3.43%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)2.87%
ROIC(5y)3.87%
NUVA Yearly ROA, ROE, ROICNUVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 5 -5 10

1.3 Margins

NUVA has a better Profit Margin (2.32%) than 74.37% of its industry peers.
In the last couple of years the Profit Margin of NUVA has declined.
With a decent Operating Margin value of 6.73%, NUVA is doing good in the industry, outperforming 74.87% of the companies in the same industry.
In the last couple of years the Operating Margin of NUVA has declined.
The Gross Margin of NUVA (71.66%) is better than 82.41% of its industry peers.
In the last couple of years the Gross Margin of NUVA has remained more or less at the same level.
Industry RankSector Rank
OM 6.73%
PM (TTM) 2.32%
GM 71.66%
OM growth 3Y-12.51%
OM growth 5Y-9.94%
PM growth 3Y-15.55%
PM growth 5Y-15.81%
GM growth 3Y-0.57%
GM growth 5Y-0.5%
NUVA Yearly Profit, Operating, Gross MarginsNUVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 20 40 60

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), NUVA is destroying value.
NUVA has more shares outstanding than it did 1 year ago.
The debt/assets ratio for NUVA has been reduced compared to a year ago.
NUVA Yearly Shares OutstandingNUVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
NUVA Yearly Total Debt VS Total AssetsNUVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B 2B 2.5B

2.2 Solvency

NUVA has an Altman-Z score of 1.91. This is not the best score and indicates that NUVA is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 1.91, NUVA perfoms like the industry average, outperforming 57.29% of the companies in the same industry.
A Debt/Equity ratio of 0.89 indicates that NUVA is somewhat dependend on debt financing.
NUVA's Debt to Equity ratio of 0.89 is on the low side compared to the rest of the industry. NUVA is outperformed by 78.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Altman-Z 1.91
ROIC/WACC0.42
WACC8.11%
NUVA Yearly LT Debt VS Equity VS FCFNUVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 200M 400M 600M 800M

2.3 Liquidity

NUVA has a Current Ratio of 1.25. This is a normal value and indicates that NUVA is financially healthy and should not expect problems in meeting its short term obligations.
NUVA has a worse Current ratio (1.25) than 89.45% of its industry peers.
A Quick Ratio of 0.65 indicates that NUVA may have some problems paying its short term obligations.
NUVA has a Quick ratio of 0.65. This is amonst the worse of the industry: NUVA underperforms 93.97% of its industry peers.
Industry RankSector Rank
Current Ratio 1.25
Quick Ratio 0.65
NUVA Yearly Current Assets VS Current LiabilitesNUVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

More info and screens

5

3. Growth

3.1 Past

NUVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.61%, which is quite good.
The Earnings Per Share has been growing slightly by 0.62% on average over the past years.
Looking at the last year, NUVA shows a small growth in Revenue. The Revenue has grown by 4.44% in the last year.
Measured over the past years, NUVA shows a small growth in Revenue. The Revenue has been growing by 3.20% on average per year.
EPS 1Y (TTM)15.61%
EPS 3Y-7.23%
EPS 5Y0.62%
EPS Q2Q%19.15%
Revenue 1Y (TTM)4.44%
Revenue growth 3Y0.96%
Revenue growth 5Y3.2%
Sales Q2Q%2.36%

3.2 Future

NUVA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.32% yearly.
NUVA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.89% yearly.
EPS Next Y13.97%
EPS Next 2Y14.82%
EPS Next 3Y14.9%
EPS Next 5Y14.32%
Revenue Next Year6.01%
Revenue Next 2Y6.22%
Revenue Next 3Y6.45%
Revenue Next 5Y6.89%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NUVA Yearly Revenue VS EstimatesNUVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
NUVA Yearly EPS VS EstimatesNUVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

NUVA is valuated rather expensively with a Price/Earnings ratio of 19.88.
86.93% of the companies in the same industry are more expensive than NUVA, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.21, NUVA is valued a bit cheaper.
A Price/Forward Earnings ratio of 15.23 indicates a correct valuation of NUVA.
Based on the Price/Forward Earnings ratio, NUVA is valued cheaply inside the industry as 88.44% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 21.70. NUVA is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 19.88
Fwd PE 15.23
NUVA Price Earnings VS Forward Price EarningsNUVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, NUVA is valued cheaply inside the industry as 93.47% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 11
NUVA Per share dataNUVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of NUVA may justify a higher PE ratio.
A more expensive valuation may be justified as NUVA's earnings are expected to grow with 14.90% in the coming years.
PEG (NY)1.42
PEG (5Y)32.2
EPS Next 2Y14.82%
EPS Next 3Y14.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NUVA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUVASIVE INC

NASDAQ:NUVA (8/31/2023, 8:10:26 PM)

After market: 39.88 +0.13 (+0.33%)

39.75

-0.91 (-2.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-02 2023-08-02/amc
Earnings (Next)11-07 2023-11-07/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners1.99%
Ins Owner Change0%
Market Cap2.08B
Analysts70.91
Price Target50.72 (27.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.04%
Min EPS beat(2)0.41%
Max EPS beat(2)7.68%
EPS beat(4)2
Avg EPS beat(4)-2.68%
Min EPS beat(4)-17.19%
Max EPS beat(4)7.68%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.05%
Min Revenue beat(2)-3.26%
Max Revenue beat(2)1.16%
Revenue beat(4)1
Avg Revenue beat(4)-2.23%
Min Revenue beat(4)-3.74%
Max Revenue beat(4)1.16%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.53%
PT rev (3m)2.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.88%
EPS NY rev (1m)0%
EPS NY rev (3m)2.33%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)-0.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 19.88
Fwd PE 15.23
P/S 1.7
P/FCF N/A
P/OCF 14.94
P/B 2.34
P/tB 24.74
EV/EBITDA 11
EPS(TTM)2
EY5.03%
EPS(NY)2.61
Fwd EY6.57%
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)2.66
OCFY6.69%
SpS23.38
BVpS17.02
TBVpS1.61
PEG (NY)1.42
PEG (5Y)32.2
Profitability
Industry RankSector Rank
ROA 1.36%
ROE 3.19%
ROCE 5.48%
ROIC 3.43%
ROICexc 3.59%
ROICexgc 6.59%
OM 6.73%
PM (TTM) 2.32%
GM 71.66%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)2.87%
ROIC(5y)3.87%
ROICexc(3y)4.12%
ROICexc(5y)4.87%
ROICexgc(3y)17.94%
ROICexgc(5y)16.07%
ROCE(3y)3.71%
ROCE(5y)5.01%
ROICexcg growth 3Y3.59%
ROICexcg growth 5Y-1.31%
ROICexc growth 3Y-7.11%
ROICexc growth 5Y-4.99%
OM growth 3Y-12.51%
OM growth 5Y-9.94%
PM growth 3Y-15.55%
PM growth 5Y-15.81%
GM growth 3Y-0.57%
GM growth 5Y-0.5%
F-Score7
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Debt/EBITDA 3.58
Cap/Depr 101.93%
Cap/Sales 11.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.25
Quick Ratio 0.65
Altman-Z 1.91
F-Score7
WACC8.11%
ROIC/WACC0.42
Cap/Depr(3y)82.61%
Cap/Depr(5y)85.69%
Cap/Sales(3y)10.64%
Cap/Sales(5y)10.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.61%
EPS 3Y-7.23%
EPS 5Y0.62%
EPS Q2Q%19.15%
EPS Next Y13.97%
EPS Next 2Y14.82%
EPS Next 3Y14.9%
EPS Next 5Y14.32%
Revenue 1Y (TTM)4.44%
Revenue growth 3Y0.96%
Revenue growth 5Y3.2%
Sales Q2Q%2.36%
Revenue Next Year6.01%
Revenue Next 2Y6.22%
Revenue Next 3Y6.45%
Revenue Next 5Y6.89%
EBIT growth 1Y45.07%
EBIT growth 3Y-11.68%
EBIT growth 5Y-7.06%
EBIT Next Year96.6%
EBIT Next 3Y33.66%
EBIT Next 5Y25.87%
FCF growth 1Y-102.72%
FCF growth 3Y-34.34%
FCF growth 5Y-14.37%
OCF growth 1Y-39.92%
OCF growth 3Y-10.42%
OCF growth 5Y-0.91%